Multimorbidity and Serological Response to SARS-CoV-2 Nine Months after 1st Vaccine Dose: European Cohort of Healthcare Workers-Orchestra Project.

Autor: Violán C; Unitat de Suport a la Recerca Metropolitana Nord, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mare de Déu de Guadalupe, 08303 Mataró, Spain.; Germans Trias i Pujol Research Institute (IGTP), Camí de les Escoles, s/n, 08916 Badalona, Spain.; Grup de REcerca en Impacte de les Malalties Cròniques i les Seves Trajectòries (GRIMTra) (2021 SGR 01537), Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mare de Déu de Guadalupe, 08303 Barcelona, Spain.; Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS) (RD21/0016/0029), Insitituto de Salud Carlos III, Av. de Monforte de Lemos, 5, 28029 Madrid, Spain.; Direcció d'Atenció Primària Metropolitana Nord Institut Català de Salut, Ctra. de Barcelona, 473, Sabadell, 08204 Barcelona, Spain.; Universitat Autónoma de Barcelona, Plaça Cívica, 08193 Bellaterra, Spain., Carrasco-Ribelles LA; Unitat de Suport a la Recerca Metropolitana Nord, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mare de Déu de Guadalupe, 08303 Mataró, Spain.; Grup de REcerca en Impacte de les Malalties Cròniques i les Seves Trajectòries (GRIMTra) (2021 SGR 01537), Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mare de Déu de Guadalupe, 08303 Barcelona, Spain.; Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS) (RD21/0016/0029), Insitituto de Salud Carlos III, Av. de Monforte de Lemos, 5, 28029 Madrid, Spain., Collatuzzo G; Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy., Ditano G; Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy., Abedini M; Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy., Janke C; Division of Infectious Diseases and Tropical Medicine, LMU Klinikum, Leopoldstraße 5, 80802 Munich, Germany., Reinkemeyer C; Division of Infectious Diseases and Tropical Medicine, LMU Klinikum, Leopoldstraße 5, 80802 Munich, Germany., Giang LTT; Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Lindwurmstrasse 4, 80337 Munich, Germany., Liviero F; Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy., Scapellato ML; Occupational Medicine Unit, University Hospital of Padova, 35128 Padova, Italy., Mauro M; Unit of Occupational Medicine, Department of Medical Sciences, University of Trieste, 34129 Trieste, Italy., Rui F; Unit of Occupational Medicine, Department of Medical Sciences, University of Trieste, 34129 Trieste, Italy., Porru S; Occupational Medicine Unit, University Hospital of Verona, 37134 Verona, Italy.; Section of Occupational Health, Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy., Spiteri G; Occupational Medicine Unit, University Hospital of Verona, 37134 Verona, Italy., Monaco MGL; Occupational Medicine Unit, University Hospital of Verona, 37134 Verona, Italy., Carta A; Occupational Medicine Unit, University Hospital of Verona, 37134 Verona, Italy.; Section of Occupational Health, Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy., Otelea M; University of Medicine and Pharmacy 'Carol Davila', 020022 Bucharest, Romania., Rascu A; University of Medicine and Pharmacy 'Carol Davila', 020022 Bucharest, Romania., Fabiánová E; Occupational Health Department, Regional Authority of Public Health, 97556 Banská Bystrica, Slovakia.; Public Health Department, Faculty of Health, Catholic University, 03401 Ružomberok, Slovakia., Klöslová Z; Occupational Health Department, Regional Authority of Public Health, 97556 Banská Bystrica, Slovakia.; Public Health Department, Faculty of Health, Catholic University, 03401 Ružomberok, Slovakia., Boffetta P; Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy., Torán-Monserrat P; Unitat de Suport a la Recerca Metropolitana Nord, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mare de Déu de Guadalupe, 08303 Mataró, Spain.; Germans Trias i Pujol Research Institute (IGTP), Camí de les Escoles, s/n, 08916 Badalona, Spain.; Direcció d'Atenció Primària Metropolitana Nord Institut Català de Salut, Ctra. de Barcelona, 473, Sabadell, 08204 Barcelona, Spain.; Department of Medicine, Faculty of Medicine, Universitat de Girona, 17001 Girona, Spain.; Multidisciplinary Research Group in Health and Society (GREMSAS) (2021 SGR 01484), Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mare de Déu de Guadalupe, 08303 Barcelona, Spain.
Jazyk: angličtina
Zdroj: Vaccines [Vaccines (Basel)] 2023 Aug 08; Vol. 11 (8). Date of Electronic Publication: 2023 Aug 08.
DOI: 10.3390/vaccines11081340
Abstrakt: Understanding antibody persistence concerning multimorbidity is crucial for vaccination policies. Our goal is to assess the link between multimorbidity and serological response to SARS-CoV-2 nine months post-first vaccine. We analyzed Healthcare Workers (HCWs) from three cohorts from Italy, and one each from Germany, Romania, Slovakia, and Spain. Seven groups of chronic diseases were analyzed. We included 2941 HCWs (78.5% female, 73.4% ≥ 40 years old). Multimorbidity was present in 6.9% of HCWs. The prevalence of each chronic condition ranged between 1.9% (cancer) to 10.3% (allergies). Two regression models were fitted, one considering the chronic conditions groups and the other considering whether HCWs had diseases from ≥2 groups. Multimorbidity was present in 6.9% of HCWs, and higher 9-months post-vaccine anti-S levels were significantly associated with having received three doses of the vaccine (RR = 2.45, CI = 1.92-3.13) and with having a prior COVID-19 infection (RR = 2.30, CI = 2.15-2.46). Conversely, lower levels were associated with higher age (RR = 0.94, CI = 0.91-0.96), more time since the last vaccine dose (RR = 0.95, CI = 0.94-0.96), and multimorbidity (RR = 0.89, CI = 0.80-1.00). Hypertension is significantly associated with lower anti-S levels (RR = 0.87, CI = 0.80-0.95). The serological response to vaccines is more inadequate in individuals with multimorbidity.
Databáze: MEDLINE
Externí odkaz: